Lung Ambition Alliance: Stronger Together 

Use of Predictive Biomarkers, Incorporating Chemotherapy—What Is Best When Using Immunotherapy in Advanced NSCLC?

Patient Advocate Comment: Amivantamab for Exon 20

Presidential Symposium Findings 

KEYNOTE-598: Dual PD-1 and CTLA-4 Checkpoint Blockade Confers No Therapeutic Benefit Beyond PD-1 Blockade Alone in PD-L1–Positive NSCLC

LCMC3 Findings Indicate Neoadjuvant Atezolizumab Safe, Efficacious in Resectable Stage IB-IIIB NSCLC

Real-World Data Show That Survival Just as Good With Carboplatin Therapy as With Cisplatin Therapy in Malignant Pleural Mesothelioma 

A Holistic Approach to Patient Care

Lung Cancer Biomarker Testing Patterns Varied Widely in Japan

Management of Long-Term Immune-Related Toxicities Needed in NSCLC

Additional ADAURA Analyses Help Support the Benefit of Adjuvant Osimertinib in Patients With Resected EGFR-Mutated NSCLC

Practice-Changing Initiatives Benefit the Medical Team, Patients